| Literature DB >> 35931864 |
Roman Kosoy1,2,3,4,5, John F Fullard6,7,8,9,10, Biao Zeng6,7,8,9,10, Jaroslav Bendl6,7,8,9,10, Pengfei Dong6,7,8,9,10, Samir Rahman6,7,8,9,10, Steven P Kleopoulos6,7,8,9,10, Zhiping Shao6,7,8,9,10, Kiran Girdhar6,7,8,9,10, Jack Humphrey7,9,11,12, Katia de Paiva Lopes7,9,11,12,13, Alexander W Charney7,10, Brian H Kopell10,11,12,14, Towfique Raj7,9,11,12, David Bennett13,15, Christopher P Kellner14, Vahram Haroutunian10,11,16, Gabriel E Hoffman17,18,19,20,21, Panos Roussos22,23,24,25,26,27,28.
Abstract
Microglia are brain myeloid cells that play a critical role in neuroimmunity and the etiology of Alzheimer's disease (AD), yet our understanding of how the genetic regulatory landscape controls microglial function and contributes to AD is limited. Here, we performed transcriptome and chromatin accessibility profiling in primary human microglia from 150 donors to identify genetically driven variation and cell-specific enhancer-promoter (E-P) interactions. Integrative fine-mapping analysis identified putative regulatory mechanisms for 21 AD risk loci, of which 18 were refined to a single gene, including 3 new candidate risk genes (KCNN4, FIBP and LRRC25). Transcription factor regulatory networks captured AD risk variation and identified SPI1 as a key putative regulator of microglia expression and AD risk. This comprehensive resource capturing variation in the human microglia regulome provides insights into the etiology of neurodegenerative disease.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35931864 PMCID： PMC9388367 DOI： 10.1038/s41588-022-01149-1
Source DB: PubMed Journal: Nat Genet ISSN： 1061-4036 Impact factor: 41.307